PROCEPT BioRobotics® Announces Preliminary Fourth Quarter Revenue of $43.3 million to $43.6 million
SAN JOSE, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) — PROCEPT BioRobotics Corporation (Nasdaq:PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported preliminary unaudited revenue for the quarter and fiscal year ended December 31, 2023.
Related news for (PRCT)
- PROCEPT BioRobotics’ Aquablation Therapy Spotlighted at 2025 AUA Annual Meeting Along with Expert-Led Workshops
- PROCEPT BioRobotics Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
- PROCEPT BioRobotics® Reports Fourth Quarter and Full Year 2024 Results
- Spruce Point Capital Management Announces Investment Opinion: Releases Report and Strong Sell Research Opinion on PROCEPT BioRobotics (NASDAQ: PRCT)
- procept biorobotics corporation announces pricing of offering of common stock